UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 9, 2016
Inotek Pharmaceuticals Corporation
(Exact name of registrant as specified in its charter)
| DELAWARE |
001-36829 |
04-3475813 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| 91 Hartwell Avenue Lexington, MA |
02421 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (781) 676-2100
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On March 9, 2016, Inotek Pharmaceuticals Corporation issued a press release announcing that the United States Patent and Trademark Office had issued a new composition-of-matter patent for its lead product candidate trabodenoson. A copy of this press release is filed herewith as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits |
| (d) | Exhibits. |
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated March 9, 2016 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 11, 2016 | INOTEK PHARMACEUTICALS CORPORATION | |||||
| By: | /s/ Dale Ritter | |||||
| Dale Ritter | ||||||
| Vice President —Finance | ||||||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated March 9, 2016 | |
Exhibit 99.1
Inotek Pharmaceuticals Strengthens Patent Estate for Lead Product Candidate Trabodenoson
LEXINGTON, Mass – March 9, 2016 – Inotek Pharmaceuticals Corporation (the “Company” or “Inotek”) (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, announced today that the United States Patent and Trademark Office (“USPTO”) issued a new composition of matter patent for its lead product candidate, trabodenoson. This patent bolsters the Company’s patent estate and extends composition of matter intellectual property protection to 2033.
Trabodenoson is an investigational agent currently in pivotal Phase 3 clinical trials for the treatment of glaucoma. Its novel mechanism of action augments the natural function of the trabecular meshwork, the primary pathway where aqueous humor is transported out of the eye.
“The finding of these crystalline forms – each described in the newly-issued patent – and our ability to control their formation, have been key to controlling the stability of trabodenoson when formulated in an eye drop. The extension of our composition of matter patent coverage to 2033 increases our ability to protect trabodenoson eye drops in the U.S. market, with extension in non-U.S. territories pending the international
applications on file,” said William McVicar, Chief Scientific Officer of Inotek.
Inotek’s patent estate also includes composition of matter patents covering the trabodenoson compound through 2026 in the U.S. and 2025 abroad, and patents relating to the use of trabodenoson for reducing intraocular pressure, which expire in 2031 in the U.S. and in 2030 if issued abroad.
About Inotek Pharmaceuticals Corporation
Inotek is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit www.inotekpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These forward-looking statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or
revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Inotek Pharmaceuticals
Inotek Contact:
Claudine Prowse, Ph.D., 781-552-4305
Vice President, Strategy and Investor Relations Officer
cprowse@inotekpharma.com